How to Survive Investor Relations


Good investor relations entails creating a story which is based on reality.

Criticaleye spoke to Tom Attenborough, Alan Bannatyne, Martin Bloom, Vanda Murray, Jamie Pike, Mike Tye, Leslie Van de Walle and Jim Wilkinson to find out what it is investors want to see and hear.

Share this with your Community


Contributors
Alan Bannatyne
Board Mentor
Criticaleye
Jamie Pike
Board Mentor
Criticaleye
Jim Wilkinson
Chief Financial Officer
Oxford Sciences Innovation PLC
Leslie Van de Walle
Board Mentor
Criticaleye
Martin Bloom
Former Board Mentor
Criticaleye
Mike Tye
Board Mentor
Criticaleye
Tom Attenborough
Head of International Business Development - Primary Markets
London Stock Exchange Group
Vanda Murray
Board Mentor
Criticaleye


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | Unlocking Value as CPO

CPOs are navigating an era of rapid disruption: shaping workforce strategy, managing an evolving talent landscape, meeting rising expectations from the Board and acting as architects of organisational transformation....


Criticaleye Asia Podcast - Mastering Regional Leadership in Asia: Driving Change Across Markets

In this episode, Yu-Wen Hsiao, Marketing and Communications Manager, APAC at Criticaleye, speaks with Kalpesh R Parmar, General Manager, Mars Snacking Asia, about leading change and building high-performing teams acr...


Click here to download this insight

BLOG | What Sets World-Class CEOs Apart in Uncertain Times?

If you're a CEO today, you’re likely feeling the pressure to be a technologist, a geopolitical expert and a visionary all at once. Markets are shifting rapidly, the operating...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 180




Lightsource bp NATS Worldpay Rolls-Royce Hitachi Solutions LACE Partners E.ON UK London Stock Exchange Group AlixPartners Aldermore Group Drax Group plc Legal & General Mayborn Group British Land GlaxoSmithKline plc Canaccord Genuity Group Inc NatWest Group